Final - June 22-23, 2022

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329 

June 22-23, 2022

PRESIDER/PRESENTER(s)

10:00 Welcome & Introductions Dr. Grace Lee (ACIP Chair)

Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

10:30 Influenza Vaccine 

Introduction Dr. Keipp Talbot (ACIP, WG Chair)

Vaccine effectiveness update Dr. Jessie Chung (CDC/NCIRD)

Influenza vaccination of older adults Dr. Lisa Grohskopf (CDC/NCIRD)

Summary, work group considerations, and proposed 2022-23 

recommendations

Dr. Lisa Grohskopf (CDC/NCIRD)

12:25 Break

12:35 Pneumococcal Vaccines

Introduction Dr. Kathy Poehling (ACIP, WG Chair)

PCV15 Pediatric Clinical Development Program – Update Dr. Natalie Banniettis (Merck)

Economic analysis and public health Impact of PCV15 use in children Dr. Andrew Leidner (CDC/NCIRD)

Summary of WG interpretation on EtR Dr. Miwako Kobayashi (CDC/NCIRD)

Proposed recommendations for PCV15 use in children Dr. Miwako Kobayashi (CDC/NCIRD)

2:05 Break 

2:15 Measles, Mumps, and Rubella (MMR) Vaccine 

Introduction Ms. Lynn Bahta (ACIP, WG Chair)

EtR and proposed recommendations Dr. Elisabeth Krow-Lucal (CDC/NCIRD)

2:55 Break

3:00 Public Comment 

3:20 Votes 

Influenza Vaccine Dr. Lisa Grohskopf (CDC/NCIRD)

Pneumococcal Vaccines Dr. Miwako Kobayashi (CDC/NCIRD)

Pneumococcal Vaccines - VFC vote Dr. Jeanne Santoli (CDC/NCIRD)

MMR Vaccine Dr. Elisabeth Krow-Lucal (CDC/NCIRD)

4:20 Break

4:30 Human Papillomavirus (HPV) Vaccine

National and state-level HPV vaccination coverage Dr. Shannon Stokley (CDC/NCIRD)

Impact of the US HPV vaccination program on HPV-associated outcomes Dr. Julia Gargano (CDC/NCIRD)

One-dose HPV vaccination – overview of current evidence Dr. Lauri Markowitz (CDC/NCIRD)

5:10 Adjourn

10:00 Welcome & Introductions Dr. Grace Lee (ACIP Chair)

Dr. Melinda Wharton (ACIP Executive Secretary, CDC)

10:15 Agency Updates

10:30 Coronavirus Disease 2019 (COVID-19) Vaccines 

Introduction Dr. Matthew Daley (ACIP, WG Chair)

Burden, prevalence and trends of long-term sequelae of

SARS-CoV-2

Dr. Melissa Briggs-Hagen (CDC/NCIRD)

Updates on safety of COVID-19 vaccines in children and adolescents Dr. Tom Shimabukuro (CDC/NCEZID)

VaST assessment Dr. Keipp Talbot (ACIP, VaST Chair)

Moderna COVID-19 vaccine (mRNA-1273): Safety, immunogenicity and 

efficacy in children and adolescents ages 6-17 years

Dr. Rituparna Das (Moderna)

Evidence to Recommendation Framework: Moderna COVID-19 vaccine in 

children and adolescents ages 6-17 years

Dr. Sara Oliver (CDC/NCIRD)

Clinical Considerations update Dr. Elisha Hall (CDC/NCIRD)

1:00 Discussion

1:10 Public Comment

1:30 Vote(s) 

Moderna COVID-19 vaccine in children ages 6-17 years Dr. Sara Oliver (CDC/NCIRD)

AGENDA ITEM

Wednesday, June 22, 2022

Thursday, June 23, 2022

page 1 of 2
Final - June 22-23, 2022

1:50 Break

1:55 Meningococcal Vaccines

Introduction Dr. Kathy Poehling (ACIP, WG Chair)

2:00 Respiratory Syncytial Virus (RSV) Vaccine

Introduction Dr. Camille Kotton (ACIP, WG Chair)

RSV virion & vaccine products Dr. Natalie Thornburg (CDC/NCIRD)

Epidemiology of RSV in children Dr. Meredith McMorrow (CDC/NCIRD)

Epidemiology of RSV in adults Dr. Fiona Havers (CDC/NCIRD)

Safety and efficacy of Nirsevimab in infants Dr. Christian Felter (Sanofi)

3:30 Break

3:40 Chikungunya Vaccines

Introduction Dr. Beth Bell (ACIP, WG Chair)

Overview of chikungunya and chikungunya vaccines Dr. Susan Hills (CDC/NCEZID)

Plans and timeline for work group activities Dr. Susan Hills (CDC/NCEZID)

4:15 Monkeypox Informational Session

Situational update Dr. Agam Rao (CDC/NCEZID)

Medical countermeasures Dr. Brett Petersen (CDC/NCEZID) 

5:00 Adjourn

Acronyms

CDC Centers for Disease Control and Prevention

CMS Centers for Medicare and Medicaid Services 

COVID-19 Coronavirus disease 2019

EtR Evidence to Recommendations Framework

FDA Food and Drug Administration

GRADE

HRSA Health Resources and Services Administration

IHS Indian Health Service

MMR Measles, Mumps, and Rubella Vaccine

NCHHSTP

NCIRD

NCEZID

NIAID National Institute of Allergy and Infectious Diseases

OIDP Office of Infectious Disease and HIV/AIDS Policy

PCV15 15-valent Pneumococcal Conjugate Vaccine 

SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2

WG Work Group

WHO World Health Organization

VE Vaccine Effectiveness

National Center for Immunization & Respiratory Diseases [of CDC/OID] 

National Center for Emerging and Zoonotic Diseases [of CDC/OID]

Grading of Recommendations Assessment, Development and Evaluation

National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] 

page 2 of 2